imatinib mesylate has been researched along with Carcinoma, Lewis Lung in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Ding, L; He, Q; Liang, G; Wu, H; Xu, X; Yang, B; Yao, F; Yao, Z; Zhang, B; Zhang, J | 1 |
| Andersson, P; Cao, Y; Feng, N; Hosaka, K; Jensen, L; Larsson, O; Li, X; Lim, S; Nakamura, M; Ohhashi, T; Rouhi, P; Seki, T; Xue, Y; Yang, X; Yang, Y | 1 |
| Chen, D; Chou, J; Falcon, BL; Hanahan, D; McDonald, DM; Pietras, K; Sennino, B | 1 |
3 other study(ies) available for imatinib mesylate and Carcinoma, Lewis Lung
| Article | Year |
|---|---|
Imatinib prevents lung cancer metastasis by inhibiting M2-like polarization of macrophages.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Polarity; Imatinib Mesylate; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; RAW 264.7 Cells; STAT6 Transcription Factor | 2018 |
Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Becaplermin; Benzamides; Carcinoma, Lewis Lung; Cell Movement; Cell Proliferation; Fibrosarcoma; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Integrin alpha1beta1; Lung Neoplasms; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Pericytes; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.
Topics: Animals; Antineoplastic Agents; Aptamers, Nucleotide; Benzamides; Benzimidazoles; Carcinoma, Lewis Lung; Cell Proliferation; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Imatinib Mesylate; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pericytes; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Treatment Outcome | 2011 |